Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01834833
Other study ID # P110601 - PHRQ1104
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2013
Est. completion date July 2017

Study information

Verified date October 2018
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the benefit of systematic appointment with a cardiologist a week after hospitalisation for acute heart failure. Randomised, endpoint: number of day alive out of hospital during 6 months


Description:

Background: the risk for rehospitalisation is very high after hospitalisation for acute heart failure. Aim: evaluate the benefit of a consultation with a cardiologist, including echocardiography and education of the patient, between 7 and 15 days after discharge, in high risk patients, identified with BNP or incomplete therapy. Parallel randomised study. The main endpoint is the number of day alive out of hospital during the 6 months post discharge; statistics intention to treat comparison of the number of days alive out of hospital in the group with consultation compared with the group without consultation. Recruitment 3 years and 4 months, follow-up 6 months. Patients included have been hospitalised in hospital BICHAT 75018 Paris, France. Financing is by the ministry of health (PHRQHOS)


Recruitment information / eligibility

Status Completed
Enrollment 326
Est. completion date July 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Criteria of inclusion :

- Patient with decompensated heart failure hospitalized in the hospital BICHAT,

- For whom is planned a return at home,

- Valid (being able to return for a consultation to the hospital)

- Having Nt-ProBNP of exit = 3500 ng /l and/or a non optimized treatment of exit - according to the doctor who has it the responsibility,

- Having signed the consent form by participation in the study.

Criteria of not inclusion :

- Age < 18 years,

- Not membership in a national insurance scheme or in the Universal Health

- Coverage (CMU)(FREE UNIVERSAL HEALTH CARE)(A patient benefiting from the Medical aid of the State (AME) cannot be included)

- Participation to another protocol of research,

- Not being reachable by telephone in 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Follow-up
Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary

Locations

Country Name City State
France Hopital Bichat Claude Bernard Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary days alive out of hospital 6 months post discharge 6 months
Secondary rehospitalisation rate at 6 months 6 months
Secondary mortality at 3 and 6 months 3 and 6 months
Secondary number of patients receiving beta-blocker at 6 months 6 months
Secondary number of patients receiving a ACEI at 6 months 6 months
Secondary QOL at 6 months 6 months
Secondary autoevaluation of improvement/alteration of the patient state at 6 months 6 months
Secondary number of patients receiving beta-blocker at 3 months 3 months
Secondary number of patients receiving a ACEI at 3 months 3 months
Secondary QOL at 3 months 3 months
Secondary autoevaluation of improvement/alteration of the patient state at 3 months 3 months
Secondary number of patients having an optimal treatment at 6 months 6 months
Secondary number of patients having an optimal treatment at 3 months 3 months
See also
  Status Clinical Trial Phase
Terminated NCT02151383 - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Phase 2
Completed NCT02135835 - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Phase 4
Recruiting NCT05556044 - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction Phase 3
Recruiting NCT04363697 - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Phase 4
Completed NCT02122640 - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department N/A
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Not yet recruiting NCT01211886 - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU) N/A
Not yet recruiting NCT06465498 - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography N/A
Recruiting NCT05276219 - Optimized Treatment of Pulmonary Edema or Congestion Phase 4
Recruiting NCT05392764 - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure Phase 3
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Completed NCT06024889 - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Phase 1/Phase 2
Terminated NCT04174794 - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting NCT05972746 - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure N/A
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A
Completed NCT02141607 - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed NCT01870778 - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF Phase 3
Recruiting NCT05986773 - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance Phase 4
Recruiting NCT04163588 - Sequential Nephron Blockade in Acute Heart Failure Phase 3
Recruiting NCT03720288 - Acetazolamide in Patients With Acute Heart Failure Phase 3